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CMR With Late Gadolinium Enhancement in
Genotype Positive–Phenotype Negative
Hypertrophic Cardiomyopathy
Ethan J. Rowin, MD,* Martin S. Maron, MD,* John R. Lesser, MD,† Barry J. Maron, MD†
RECENT REPORTS HAVE DEMONSTRATED THAT SOME PAT IENTS WITH
HYPERTROPHIC CARDIOMYOPATHY (HCM) WHO CARRY a pathogenic sarcomere
mutation without left ventricular (LV) hypertrophy (genotype positive–phenotype negative [GP])
may nevertheless show morphological abnormalities, including: myocardial crypts, elongated mitral
valve leaﬂets, biomarkers of ﬁbrosis, or diastolic dysfunction (1). In the present paper (Figs. 1, 2, 3, and 4), we
resent another structural abnormality in GP HCM patients, in whom cardiac magnetic resonance
CMR) identiﬁed substantial late gadolinium enhancement (LGE) indicative of myocardial ﬁbrosis (2).
he precise pathophysiological mechanism responsible for LGE in HCM remains uncertain, but may be
elated to repetitive bouts of small vessel ischemia leading to myocyte cell death and ultimately repair
n the form of replacement ﬁbrosis.
n these 4 unrelated GP HCM patients (Figs. 1, 3, and 4), LGE represents a potential CMR-marker of
gene-positive status, with potential implications on management strategies. In HCM family members
who can undergo deﬁnitive genetic testing, identiﬁcation of LGE by CMR underscores the importance
of pursuing genotyping to achieve deﬁnitive HCM diagnosis. In addition, if genetic testing cannot be
performed or is ambiguous, the identiﬁcation of LGE in an HCM relative without LV hypertrophy should
prompt close surveillance with imaging to detect development of the phenotype. At present, it is
uncertain whether LGE in GP HCM patients is a marker of increased risk for adverse disease-related
complications, including sudden death and heart failure. Nevertheless, these observations underscore
the emerging principle that even nonhypertrophied LV myocardium in HCM may be structurally
abnormal and suggest the need for longitudinal studies to determine the prognostic signiﬁcance of
such ﬁndings.
These cases stand as examples of the power of complimentary imaging with CMR in the evaluation of
HCM patients. In particular, our observations underscore the potential value of routine CMR imaging as
part of screening assessments in HCM family members, in conjunction with echocardiography (and
12-lead electrocardiogram).
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120Figure 1. LGE in a Genotype-Positive/Phenotype-Negative HCM Patient
Cine and contrast-enhanced cardiac magnetic resonance (CMR) in a 44-year-old asymptomatic genotype-positive/phenotype-negative HCM woman with -tropo-
myosin mutation (TPM1 Asp175Asn), who underwent cardiovascular evaluation after the diagnosis of HCM in her 21 year-old son (Figure 2). (A) Cardiac magnetic
resonance (CMR) end-diastolic short-axis and (B) 2-chamber views demonstrate normal left ventricle (LV) wall thicknesses (maximal wall dimension, 12 mm).
(C to F) Contrast-enhanced CMR imaging views after intravenous injection of gadolinium showing extensive areas of late gadolinium enhancement (LGE), includ-
ing involvement of the anterior (thin arrows) and posterior ventricular septum (thick arrows) on (C) apical and (D) mid-LV short axis images, anterior (thin
arrows) and posterior (inferior) LV free wall (thick arrows) on (E) 2-chamber long-axis images and (F) posterior septum (arrows) on 4-chamber long-axis image;
global ejection fraction and segmental LV wall motion were normal. LA  left atrium; RA  right atrium; RV  right ventricle; VS  ventricular septum.Figure 2. LGE in HCM Patient With LV Hypertrophy
Cine and contrast-enhanced CMR in the 21-year-old son, of the patient in Figure 1, with HCM. The patient initially presented after an episode of supraventricular
tachycardia. (A and B) CMR end-diastolic mid-ventricular short-axis (A) and 2-chamber views (B) demonstrating an area of increased wall thickness of 23 mm in
the basal posterior septum (A, asterisk) also involving the posterior (inferior) free wall (B, asterisk). (C and D) Identical imaging views to (A) and (B) in the
same patient after intravenous injection of gadolinium, showing focal LGE (i.e., myocardial ﬁbrosis) conﬁned to the hypertrophied posterior septum (C,
arrow) and inferior wall (D, arrows). The patient was found to have an HCM disease-causing mutation in the -tropomyosin gene (TPM1 Asp175Asn).
Abbreviations as in Figure 1.
at the LV apex (arrows); global ejection fraction and segmental LV wall motion were normal. Abbreviations as in Figure 1.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 , 2 0 1 2
J A N U A R Y 2 0 1 2 : 1 1 9 – 2 2
Rowin et al.
CMR in Genotype-Positive/Phenotype-Negative HCM Patients
121Figure 4. LGE in Genotype-Positive/Phenotype-Negative HCM Patient and in a Patient With Family History of HCM
Cine and contrast-enhanced CMR images of a 20-year-old asymptomatic genotype positive/phenotype negative HCM woman with a beta-myosin heavy chain mutation
(MYH7 Arg663His). Both her father and paternal uncle have HCM and required heart transplantation in mid-life due to refractory advanced heart failure (“end-stage”).
(A and B) CMR end-diastolic basal short-axis images demonstrating an asymmetric pattern of LV hypertrophy with relatively greater wall thickness in the basal anterior
septum (A, asterisk), although maximal LV thickness was normal (i.e., 10 mm). (B) Basal short-axis contrast-enhanced CMR image showing a focal area of predominantly
mid-myocardial LGE in the anterior septum (thick arrow) and posterior septum (thin arrow); global ejection fraction and segmental LV wall motion were normal. (C and
D) 40-year-old man with extensive family history of HCM. Informative genotyping proved impractical in this family. End-diastolic short-axis image (C) demonstrating nor-Figure 3. Genotype-Positive/Phenotype-Negative Young Athlete With LGE
Cine and contrast-enhanced CMR images in an asymptomatic 21-year-old genotype positive/phenotype negative male college basketball player with a myosin-
binding protein C mutation (MYBPC3 Arg 1228Cys) who came to recognition due to identiﬁcation of a heart murmur. (A) CMR end-diastolic 2-chamber image
demonstrating normal LV wall thickness (maximal wall thickness, 12 mm). (B) Contrast-enhanced CMR in the identical imaging view showing subendocardial LGEmal LV wall thickness (maximal, 12 mm). (D) After intravenous injection of gadolinium, focal LGE is present in the posterior septum. Abbreviations as in Figure 1.
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